KNSA
Kiniksa Pharmaceuticals International, plc
Price Chart
Latest Quote
$56.89
-2.24 (-3.79%)
Current Price
| Previous Close | $59.13 |
| Open | $58.84 |
| Day High | $59.73 |
| Day Low | $56.86 |
| Volume | 675,087 |
Stock Information
| Shares Outstanding | 46.30M |
| Total Debt | $9.03M |
| Cash Equivalents | $468.09M |
| Revenue | $754.04M |
| Net Income | $73.06M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.38B |
| P/E Ratio | 62.52 |
| EPS (TTM) | $0.91 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.92B |
| Sales | $754.04M |
| Income | $73.06M |
| Book/sh | $8.22 |
| Cash/sh | $10.11 |
| Employees | 366 |
Financial Ratios
| Quick Ratio | 3.14 |
| Current Ratio | 3.79 |
| Debt/Eq | 1.49 |
| EPS Growth TTM | 164.60% |
Returns & Margins
| ROA | 8.18% |
| ROE | 13.74% |
| Gross Margin | 54.65% |
| Operating Margin | 13.66% |
| Profit Margin | 9.69% |
Ownership
| Insider Ownership | 3.58% |
| Institutional Ownership | 102.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 32.37 |
| P/S | 5.80 |
| P/B | 6.92 |
Analyst Data
| Recommendation | none |
| Target Price | $63.50 |
Technical Indicators
| SMA20 | $51.86 |
| SMA50 | $51.99 |
| SMA200 | $44.42 |
| RSI | 75.13 |
| ATR | 2.0956 |
| Shares Float | 39.32M |
| Short Float | 8.01% |
| Short Ratio | 4.95 |
| Volatility | 0.12 |
| Rel Volume | 1.14 |
Performance History
| Week | +4.94% |
| Month | +7.62% |
| Quarter | +24.11% |
| 6 Months | +30.72% |
| YTD | +35.44% |
| Year | +95.77% |
| 3 Years | +254.01% |
| 5 Years | +285.43% |
| 10 Years | +193.10% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $56.89 | 675,087 |
| 2026-06-24 | $59.13 | 1,053,400 |
| 2026-06-23 | $59.49 | 771,700 |
| 2026-06-22 | $57.13 | 609,100 |
| 2026-06-18 | $55.11 | 781,000 |
| 2026-06-17 | $54.21 | 644,700 |
| 2026-06-16 | $52.30 | 373,500 |
| 2026-06-15 | $52.34 | 627,200 |
| 2026-06-12 | $51.89 | 362,800 |
| 2026-06-11 | $51.58 | 624,200 |
| 2026-06-10 | $49.27 | 462,700 |
| 2026-06-09 | $48.70 | 522,400 |
| 2026-06-08 | $49.04 | 443,900 |
| 2026-06-05 | $48.42 | 344,500 |
| 2026-06-04 | $49.23 | 470,400 |
| 2026-06-03 | $47.85 | 496,400 |
| 2026-06-02 | $46.92 | 645,600 |
| 2026-06-01 | $48.43 | 750,300 |
| 2026-05-29 | $48.38 | 722,100 |
| 2026-05-28 | $50.84 | 486,900 |
| 2026-05-27 | $51.84 | 612,500 |
| 2026-05-26 | $52.86 | 551,300 |
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
đ° Latest News
Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View
Investor's Business Daily âĸ 2026-06-23T19:11:25Z
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
Zacks âĸ 2026-06-19T12:55:02Z
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Zacks âĸ 2026-06-16T16:00:04Z
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Zacks âĸ 2026-06-16T14:17:00Z
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
Zacks âĸ 2026-06-16T14:15:00Z
High Growth Tech Stocks in the US for May 2026
Simply Wall St. âĸ 2026-05-26T17:38:33Z
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
MarketBeat âĸ 2026-05-23T11:50:00Z
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve
Simply Wall St. âĸ 2026-05-08T14:59:40Z
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance
Simply Wall St. âĸ 2026-05-02T01:18:19Z
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
Insider Monkey âĸ 2026-05-01T07:58:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $307,218,000 | $60,910,000 | $33,407,000 | $22,895,000 |
| Cost Of Revenue | $307,218,000 | $60,910,000 | $33,407,000 | $22,895,000 |
| Total Revenue | $677,564,000 | $423,239,000 | $270,259,000 | $220,180,000 |
| Operating Revenue | $677,564,000 | $423,239,000 | $270,259,000 | $220,180,000 |
| Expenses | ||||
| Total Expenses | $600,343,000 | $468,855,000 | $295,455,000 | $210,407,000 |
| Other Income Expense | $11,647,000 | $9,464,000 | $8,544,000 | $1,253,000 |
| Other Non Operating Income Expenses | $11,647,000 | $9,464,000 | $8,544,000 | $1,253,000 |
| Operating Expense | $293,125,000 | $407,945,000 | $262,048,000 | $187,512,000 |
| Other Operating Expenses | - | $128,311,000 | $56,524,000 | $24,071,000 |
| Net Non Operating Interest Income Expense | - | - | - | $1,253,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Normalized Income | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Net Income From Continuing And Discontinued Operation | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Total Operating Income As Reported | $77,221,000 | $-45,616,000 | $-25,196,000 | $9,773,000 |
| Net Income Common Stockholders | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Net Income | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Net Income Including Noncontrolling Interests | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Net Income Continuous Operations | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Pretax Income | $88,868,000 | $-36,152,000 | $-16,652,000 | $11,026,000 |
| Operating Income | $77,221,000 | $-45,616,000 | $-25,196,000 | $9,773,000 |
| Gross Profit | $370,346,000 | $362,329,000 | $236,852,000 | $197,285,000 |
| Net Interest Income | - | - | - | $1,253,000 |
| Interest Income | - | - | - | $1,253,000 |
| Interest Income Non Operating | - | - | - | $1,253,000 |
| Per Share | ||||
| Diluted EPS | $0.75 | $-0.60 | $0.20 | $2.60 |
| Basic EPS | $0.80 | $-0.60 | $0.20 | $2.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $78,775,000 | $-43,921,000 | $-22,855,000 | $12,175,000 |
| Reconciled Depreciation | $1,554,000 | $1,695,000 | $2,341,000 | $2,402,000 |
| EBITDA (Bullshit earnings) | $78,775,000 | $-43,921,000 | $-22,855,000 | $12,175,000 |
| EBIT | $77,221,000 | $-45,616,000 | $-25,196,000 | $9,773,000 |
| Diluted Average Shares | $78,979,030 | $71,424,159 | $71,922,915 | $70,421,322 |
| Basic Average Shares | $74,200,924 | $71,424,159 | $70,058,952 | $69,382,275 |
| Diluted NI Availto Com Stockholders | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Tax Provision | $29,863,000 | $7,041,000 | $-30,736,000 | $-172,337,000 |
| Research And Development | $96,853,000 | $111,623,000 | $76,097,000 | $65,490,000 |
| Selling General And Administration | $196,272,000 | $168,011,000 | $129,427,000 | $97,951,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $552,356,000 | $422,186,000 | $421,589,000 | $377,899,000 |
| Total Assets | $763,633,000 | $580,553,000 | $526,322,000 | $459,672,000 |
| Total Non Current Assets | $236,456,000 | $248,754,000 | $250,025,000 | $216,612,000 |
| Other Non Current Assets | $11,307,000 | $10,315,000 | $827,000 | $5,824,000 |
| Non Current Deferred Assets | $198,149,000 | $211,151,000 | $219,283,000 | $185,495,000 |
| Non Current Deferred Taxes Assets | $198,149,000 | $211,151,000 | $219,283,000 | $185,495,000 |
| Goodwill And Other Intangible Assets | $15,250,000 | $16,250,000 | $17,250,000 | $18,250,000 |
| Other Intangible Assets | $15,250,000 | $16,250,000 | $17,250,000 | $18,250,000 |
| Current Assets | $527,177,000 | $331,799,000 | $276,297,000 | $243,060,000 |
| Other Current Assets | $42,614,000 | $20,084,000 | $17,538,000 | $10,537,000 |
| Inventory | $54,895,000 | $26,364,000 | $31,122,000 | $21,599,000 |
| Receivables | $15,594,000 | $41,724,000 | $21,266,000 | $20,316,000 |
| Accounts Receivable | $15,594,000 | $41,724,000 | $21,266,000 | $12,660,000 |
| Cash Cash Equivalents And Short Term Investments | $414,074,000 | $243,627,000 | $206,371,000 | $190,608,000 |
| Cash And Cash Equivalents | $165,596,000 | $183,581,000 | $107,954,000 | $122,715,000 |
| Other Receivables | - | - | - | $7,656,000 |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $9,497,000 | $9,855,000 | $12,258,000 | $5,919,000 |
| Long Term Debt And Capital Lease Obligation | $6,510,000 | $7,862,000 | $10,005,000 | $2,618,000 |
| Current Debt And Capital Lease Obligation | $2,987,000 | $1,993,000 | $2,253,000 | $3,301,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $196,027,000 | $142,117,000 | $87,483,000 | $63,523,000 |
| Total Non Current Liabilities Net Minority Interest | $56,843,000 | $41,496,000 | $23,817,000 | $16,457,000 |
| Other Non Current Liabilities | $18,522,000 | $1,823,000 | $1,858,000 | $1,839,000 |
| Non Current Deferred Liabilities | $31,811,000 | $31,811,000 | $11,954,000 | $12,000,000 |
| Current Liabilities | $139,184,000 | $100,621,000 | $63,666,000 | $47,066,000 |
| Other Current Liabilities | $22,134,000 | $16,077,000 | $8,193,000 | $5,754,000 |
| Payables And Accrued Expenses | $92,626,000 | $65,505,000 | $36,959,000 | $26,798,000 |
| Payables | $2,028,000 | $2,039,000 | $8,246,000 | $7,899,000 |
| Accounts Payable | $2,028,000 | $2,039,000 | $8,246,000 | $7,899,000 |
| Current Deferred Liabilities | - | $0 | $307,000 | $0 |
| Equity | ||||
| Common Stock Equity | $567,606,000 | $438,436,000 | $438,839,000 | $396,149,000 |
| Total Equity Gross Minority Interest | $567,606,000 | $438,436,000 | $438,839,000 | $396,149,000 |
| Stockholders Equity | $567,606,000 | $438,436,000 | $438,839,000 | $396,149,000 |
| Gains Losses Not Affecting Retained Earnings | $-25,000 | $-163,000 | $6,000 | $44,000 |
| Other Equity Adjustments | $-25,000 | $-163,000 | $6,000 | $44,000 |
| Retained Earnings | $-462,138,000 | $-521,143,000 | $-477,950,000 | $-492,034,000 |
| Other | ||||
| Ordinary Shares Number | $76,294,164 | $72,516,059 | $70,460,617 | $69,697,503 |
| Share Issued | $76,294,164 | $72,516,059 | $70,460,617 | $69,697,503 |
| Tangible Book Value | $552,356,000 | $422,186,000 | $421,589,000 | $377,899,000 |
| Invested Capital | $567,606,000 | $438,436,000 | $438,839,000 | $396,149,000 |
| Working Capital | $387,993,000 | $231,178,000 | $212,631,000 | $195,994,000 |
| Capital Lease Obligations | $9,497,000 | $9,855,000 | $12,258,000 | $5,919,000 |
| Total Capitalization | $567,606,000 | $438,436,000 | $438,839,000 | $396,149,000 |
| Additional Paid In Capital | $1,029,748,000 | $959,722,000 | $916,763,000 | $888,120,000 |
| Capital Stock | $21,000 | $20,000 | $20,000 | $19,000 |
| Common Stock | $21,000 | $20,000 | $20,000 | $19,000 |
| Non Current Deferred Revenue | $31,811,000 | $31,811,000 | $11,954,000 | $12,000,000 |
| Long Term Capital Lease Obligation | $6,510,000 | $7,862,000 | $10,005,000 | $2,618,000 |
| Current Capital Lease Obligation | $2,987,000 | $1,993,000 | $2,253,000 | $3,301,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $21,437,000 | $17,046,000 | $15,954,000 | $11,213,000 |
| Current Accrued Expenses | $90,598,000 | $63,466,000 | $28,713,000 | $18,899,000 |
| Net PPE | $11,750,000 | $11,038,000 | $12,665,000 | $7,043,000 |
| Accumulated Depreciation | $-7,230,000 | $-8,193,000 | $-7,785,000 | $-6,859,000 |
| Gross PPE | $18,980,000 | $19,231,000 | $20,450,000 | $13,902,000 |
| Leases | $4,639,000 | $3,931,000 | $3,931,000 | $3,931,000 |
| Construction In Progress | $255,000 | $155,000 | $13,000 | $0 |
| Other Properties | $13,813,000 | $14,583,000 | $15,903,000 | $9,402,000 |
| Machinery Furniture Equipment | $273,000 | $562,000 | $603,000 | $569,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-5,027,000 | $-4,854,000 | $0 | - |
| Finished Goods | $20,555,000 | $21,246,000 | $12,864,000 | $15,287,000 |
| Work In Process | $29,399,000 | $0 | $18,258,000 | $6,312,000 |
| Raw Materials | $9,968,000 | $9,972,000 | $0 | $0 |
| Other Short Term Investments | $248,478,000 | $60,046,000 | $98,417,000 | $67,893,000 |
| Current Deferred Revenue | - | $0 | $307,000 | $0 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $136,417,000 | $25,412,000 | $13,171,000 | $5,702,000 |
| Operating Activities | ||||
| Operating Cash Flow | $137,985,000 | $25,689,000 | $13,301,000 | $5,807,000 |
| Cash Flow From Continuing Operating Activities | $137,985,000 | $25,689,000 | $13,301,000 | $5,807,000 |
| Operating Gains Losses | $-120,000 | $-24,000 | $179,000 | $33,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,568,000 | $-277,000 | $-130,000 | $-105,000 |
| Investing Cash Flow | $-188,993,000 | $37,672,000 | $-29,557,000 | $-8,078,000 |
| Cash Flow From Continuing Investing Activities | $-188,993,000 | $37,672,000 | $-29,557,000 | $-8,078,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-7,730,000 | $-4,984,000 | $-2,206,000 | $-901,000 |
| Financing Cash Flow | $33,023,000 | $12,266,000 | $1,495,000 | $2,516,000 |
| Cash Flow From Continuing Financing Activities | $33,023,000 | $12,266,000 | $1,495,000 | $2,516,000 |
| Net Common Stock Issuance | $-7,730,000 | $-4,984,000 | $-2,206,000 | $-901,000 |
| Issuance Of Capital Stock | - | - | - | $3,417,000 |
| Common Stock Issuance | - | - | - | $3,417,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $3,012,000 | $2,003,000 | $5,605,000 | $10,689,000 |
| End Cash Position | $165,596,000 | $183,581,000 | $107,954,000 | $122,715,000 |
| Beginning Cash Position | $183,581,000 | $107,954,000 | $122,715,000 | $122,470,000 |
| Changes In Cash | $-17,985,000 | $75,627,000 | $-14,761,000 | $245,000 |
| Proceeds From Stock Option Exercised | $40,753,000 | $17,250,000 | $3,701,000 | $3,417,000 |
| Common Stock Payments | $-7,730,000 | $-4,984,000 | $-2,206,000 | $-901,000 |
| Net Investment Purchase And Sale | $-187,425,000 | $37,924,000 | $-29,427,000 | $-8,064,000 |
| Sale Of Investment | $199,490,000 | $239,938,000 | $175,506,000 | $127,800,000 |
| Purchase Of Investment | $-386,915,000 | $-202,014,000 | $-204,933,000 | $-135,864,000 |
| Net PPE Purchase And Sale | $-1,568,000 | $-252,000 | $-130,000 | $-14,000 |
| Sale Of PPE | $0 | $25,000 | $0 | $91,000 |
| Purchase Of PPE | $-1,568,000 | $-277,000 | $-130,000 | $-105,000 |
| Change In Working Capital | $24,791,000 | $24,809,000 | $1,350,000 | $-22,575,000 |
| Change In Other Current Liabilities | $13,244,000 | $-4,019,000 | $-3,242,000 | $-1,438,000 |
| Change In Other Current Assets | $-1,210,000 | $-9,735,000 | $4,584,000 | $2,654,000 |
| Change In Payables And Accrued Expense | $37,639,000 | $37,423,000 | $17,287,000 | $2,322,000 |
| Change In Accrued Expense | $37,497,000 | $43,729,000 | $16,940,000 | $-3,709,000 |
| Change In Payable | $142,000 | $-6,306,000 | $347,000 | $6,031,000 |
| Change In Account Payable | $142,000 | $-6,306,000 | $347,000 | $6,031,000 |
| Change In Prepaid Assets | $-22,481,000 | $-2,710,000 | $-7,067,000 | $-3,858,000 |
| Change In Inventory | $-28,531,000 | $4,758,000 | $-9,523,000 | $-17,924,000 |
| Change In Receivables | $26,130,000 | $-20,458,000 | $-950,000 | $-16,331,000 |
| Changes In Account Receivables | $26,130,000 | $-20,458,000 | $-8,606,000 | $-8,675,000 |
| Other Non Cash Items | $3,666,000 | $3,136,000 | $3,054,000 | $3,041,000 |
| Stock Based Compensation | $37,003,000 | $30,693,000 | $27,149,000 | $25,120,000 |
| Amortization Of Securities | $-916,000 | $441,000 | $-1,068,000 | $-82,000 |
| Deferred Tax | $13,002,000 | $8,132,000 | $-33,788,000 | $-185,495,000 |
| Deferred Income Tax | $13,002,000 | $8,132,000 | $-33,788,000 | $-185,495,000 |
| Depreciation Amortization Depletion | $1,554,000 | $1,695,000 | $2,341,000 | $2,402,000 |
| Depreciation And Amortization | $1,554,000 | $1,695,000 | $2,341,000 | $2,402,000 |
| Gain Loss On Sale Of PPE | $-120,000 | $-24,000 | $179,000 | $33,000 |
| Net Income From Continuing Operations | $59,005,000 | $-43,193,000 | $14,084,000 | $183,363,000 |
| Change In Other Working Capital | - | $19,550,000 | $261,000 | $12,000,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
Fetched: 2026-06-23